Aerpio Pharmaceuticals is a biopharmaceutical company focused on advancing first-in-class treatments for ocular disease. Aerpioâs lead product candidate, AKB-9778, a small molecule activator of the Tie-2 pathway, is being developed for the treatment of non-proliferative diabetic retinopathy. In contrast to marketed treatments for non-proliferative diabetic retinopathy that are administered by a physician via intraocular injection, AKB-9778 is delivered systemically by self-administered subcutaneous injection. We believe this delivery method provides an opportunity to treat patients at an earlier stage of disease, potentially reducing the likelihood of these patients developing vision-threatening complications. Source
No articles found.
Aridis Pharmaceuticals, Inc. is a biopharmaceutical company focused on the develop...
Aridis Pharmaceuticals, Inc. is a biopharmaceut...
crooru is an on-demand, location-based app that connects health care staff and nur...
crooru is an on-demand, location-based app that...
Founded in 1941 in Tokyo, Japan, Hoya is a global med-tech company, and a leading ...
Founded in 1941 in Tokyo, Japan, Hoya is a glob...
Itamar Medical Ltd. is a publicly traded medical device company (TASE:ITMR) based ...
Itamar Medical Ltd. is a publicly traded medica...
BASi provides drug discovery and development services and analytical instruments t...
BASi provides drug discovery and development se...
Semler Scientific, Inc. is an emerging medical risk-assessment company whose diagn...
Semler Scientific, Inc. is an emerging medical ...
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company seeking to advance targe...
AVEO Pharmaceuticals, Inc. is a biopharmaceutic...
Join the National Investor Network and get the latest information with your interests in mind.